TITLE:
Current Understanding of Papillary Thyroid Carcinoma
AUTHORS:
Rodrigo Arrangoiz, Jeronimo Garcialopez De Llano, Maria Fernanda Mijares, Gonzalo Fernandez-Christlieb, Vanitha Vasudevan, Amit Sastry, Adrian Legaspi, Jennifer Fernandez, Frank de la Cruz, Fernando Cordera, Daniel Margain
KEYWORDS:
Thyroid Cancer, Papillary Thyroid Cancer, Papillary Thyroid Microcarcinoma, Thyroid Nodule, Thyroid Cancer Treatment, Molecular Studies for Thyroid Cancer
JOURNAL NAME:
International Journal of Otolaryngology and Head & Neck Surgery,
Vol.10 No.3,
May
25,
2021
ABSTRACT: The term thyroid neoplasm incorporates tumors that originate from follicular cells and those that arise from parafollicular cells (C cells). Differentiated thyroid cancer, which originates from follicular cells, includes papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), oncocytic cell carcinoma (Hürthle), poorly differentiated carcinoma, and anaplastic thyroid carcinoma (ATC). PTC tends to have an indolent clinical course with low morbidity and mortality. However, this entity has a broad range of biological and clinical behavior that can result in disease recurrence and death, depending on patient and tumor characteristics and the initial treatment approach. PTC is the most common form of well-differentiated thyroid cancer (WDTC) and based on the most recent statistics, accounts for approximately 89.4% of all thyroid malignancies. PTC appears as an irregular solid or cystic nodule in normal thyroid parenchyma. PTC has the propensity for lymphatic invasion, but it is less likely to have hematogenous spread. Around 11% of patients with PTC present with distant metastases outside the neck and mediastinum. This manuscript with review the current understanding of the epidemiology, pathology, molecular characteristics, prognostic factors, and dynamic risk stratification of PTC centered on an evidence-based and personalized approach.